Cell-Free Vascular Grafts and Graft Materials for Cellular Recruitment
Summary
USPTO published patent application US20260097149A1 for cell-free vascular graft materials incorporating bispecific binding partners with luminal and cellular binding domains for cellular recruitment. The application, filed June 26, 2023 under Application No. 18880781, covers fusion peptides with heparin and monocyte binding domains, methods of making the grafts, and methods of use including A-TEV technology.
What changed
USPTO published patent application US20260097149A1 for cell-free vascular graft materials and implantable vascular grafts incorporating bispecific binding partners with luminal binding domains and cellular binding domains, along with fusion peptides featuring heparin binding domains and monocyte binding domains. The application covers A-TEV technology, methods of manufacturing, and methods of use.
Medical device manufacturers and researchers in the vascular implant space should monitor the prosecution of this application to assess potential freedom-to-operate implications and to identify emerging technology trends in cell-free graft designs that may influence future product development strategies.
What to do next
- Monitor for updates
Archived snapshot
Apr 13, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CELL FREE VASCULAR GRAFTS AND GRAFT MATERIALS FOR CELLULAR RECRUITMENT
Application US20260097149A1 Kind: A1 Apr 09, 2026
Inventors
Stelios ANDREADIS, Randall SMITH, Bita NASIRI
Abstract
The present disclosure relates to an implantable vascular graft material, including: a substrate including a graft material, the substrate defining a top surface and a bottom surface; and one or more bispecific binding partners having a luminal binding domain bound to the top surface and one or more cellular binding domains. In embodiments, the disclosure includes an implantable vascular graft including: a tubular base layer including a graft material, the tubular base layer defining a luminal surface and an abluminal surface; and a fusion peptide having a heparin binding domain bound to the luminal surface and one or more monocyte binding domains. In embodiments, the present disclosure provides one or more implantable vascular grafts such as A-TEVs, methods of making vascular grafts, methods of use, and the like.
CPC Classifications
A61L 27/34 A61L 27/54 C07K 14/001 A61L 2300/236 A61L 2300/25 A61L 2300/606 A61L 2430/20
Filing Date
2023-06-26
Application No.
18880781
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.